2017 American Transplant Congress
HLA Mismatching Does Not Have an Impact on Graft or Patient Survival in Simultaneous Kidney-Pancreas Transplantation. A Single Institution Experience.
Indiana University Health, Indianapolis
Purpose: There is conflicting data on whether the level and type of HLA mismatching (MM) has an impact on pancreas, kidney, or patient survival in…2017 American Transplant Congress
Effect of HLA-DQ Mismatch on Efficacy Outcomes and Renal Function in Kidney Transplant Recipients: Subanalysis from the ELEVATE Study.
1ELEVATE Study Group, Köln, Germany; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Human leukocyte antigen (HLA)-DQ mismatches are often associated with acute rejection, independent of mismatches at other loci. Previous analysis from the ELEVATE (NCT01114529) study…2017 American Transplant Congress
Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study.
Purpose: High levels of human leukocyte antigen (HLA) mismatches are a key determinant of kidney allograft survival. Here, we present 24-month (M) subanalysis of the…2017 American Transplant Congress
The Outcome of 0 Mismatch Kidney in Pediatric Population with High Immunologic. The Impact of Induction Therapy. An Analysis of UNOS Database.
Surgery, State University New York, Syracuse, NY
Background: 0 mismatch kidneys have superior outcomes in primary transplant recipient. We performed Analysis UNOS database to determine the outcome of high PRA transplant pediatric…2016 American Transplant Congress
Epitope Load Is Predictive of De Novo Donor Specific Antibodies Occurrence in Renal Transplant Recipients After Conversion from Cyclosporine to Everolimus.
IntroductionThe degree of HLA compatibility between donor and recipient is an important risk factor of developing de novo DSA, but misjudged by the number of…2016 American Transplant Congress
Immunogenic HLA-DR Eplet Mismatches as Predictors of Transplant Glomerulopathy.
BackgroundThe number of HLA-DR eplet mismatches (eplet load) is a risk factor for the development of anti-HLA antibodies and transplant glomerulopathy (TG). In the case…2016 American Transplant Congress
Highly Sensitized Patients Transplanted via the Eurotransplant Acceptable Mismatch Program Have Excellent Long-Term Graft Survival.
Eurotransplant Reference Laboratory, Leiden University Medical Center, Leiden, Netherlands.
The Eurotransplant Acceptable Mismatch (AM) program has been initiated 25 years ago in order to enhance transplantation of highly sensitized renal transplant candidates. Instead of…2016 American Transplant Congress
Zero and One Mismathing for HLA DR10,14,16 Produces Increased Kidney Graft Survival.
Aims: HLA DR matching has shown measureable significant effects in kidney graft survival. Part and parcel of this association is the HLA Class II allele…2016 American Transplant Congress
Do Highly Sensitized Recipients Benefit from the Immunological Advantages of Zero Mismatched (0MM) Deceased Donors (DD) Kidney Allografts?
HLA 0MM DD transplants have superior outcomes compared with outcomes for grafts with ≥1 HLA mismatches, but when past reports analyzed 0MM outcomes in DD,…2016 American Transplant Congress
Complex Constellation of HLA Antibodies Contributes to Decreasing Trend of Transplant Rate in Candidates with 100% CPRA.
The key component of new KAS is offering an increased priority for sensitized candidates. While transplants (tx) have increased six-fold for recipients with a CPRA…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- Next Page »